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Abstract Biosimilars are similar, but non-identical, versions
of existing biological drugs for which patents have expired.
Despite the rigorous approval process for biosimilars, con-
cerns have been expressed about the efficacy and safety of
these products in clinical practice. Biosimilars of filgrastim,
based on the originator product Neupogen®, have been avail-
able since 2008 and are now in widespread clinical use in
Europe and elsewhere. Three biosimilar G-CSFs have been
approved based on a combination of physicochemical and
biological protein characterisation, pharmacokinetic and phar-
macodynamic assessment in healthy volunteers and efficacy
and safety data in patients with cancer. To assess whether
biosimilars are effective in the real-world clinical practice
setting, a pooled analysis of five post-approval studies of
biosimilar G-CSF (Zarzio®) that included 1,302 adult patients
who received at least one cycle of chemotherapy with G-CSF
support for the prevention of neutropenia was conducted. A
total of 36% of patients had a febrile neutropenia risk of >20%,
while 39.6 % had a risk of 10–20 % based on chemotherapy
regimen. The occurrence of severe or febrile neutropenia was
within the range of that observed in previous studies of origi-
nator G-CSF. In addition, the safety profile of Zarzio® was
consistent with that reported for originator G-CSF and the
known safety profile of G-CSF. Initial concerns about the use
of biosimilars, at least with regard to biosimilar G-CSFs, appear
to be unfounded. Adoption of cost-effective biosimilars should
help reduce healthcare costs and improve patient access to
biological treatments.
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Introduction
Biosimilars are similar, but non-identical, versions of origi-
nator biological drugs for which patents have expired. Reg-
ulatory approval for biosimilars is provided on the basis of
comparable quality, safety and efficacy to the originator
product rather than on the need to show a positive risk–
benefit assessment per se since this has already been proven
for the originator. In Europe, the European Medicines Agen-
cy (EMA) has developed a specific regulatory pathway for
biosimilars [1–3]. In the USA, the Food and Drug Adminis-
tration released a guidance draft for the regulatory review of
biosimilars in early 2012 [4].
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Several biosimilar products have now been approved in
Europe, including versions of human growth hormone,
epoetin alfa and filgrastim. Biosimilars of filgrastim, based
on the originator product Neupogen® (Amgen), have been
available since 2008 and are now in widespread clinical use.
Three biosimilars of filgrastim have been approved, although
versions of the same product may be marketed under differ-
ent names. These are Zarzio®/Filgrastim Hexal® (Sandoz
Biopharmaceuticals, a Novartis Company), Tevagrastim®/
Ratiograstim®/Biograstim® (previously referred to as XM02)
(Teva) and Nivestim® (Hospira) [5]. Widespread acceptance of
biosimilar G-CSF in oncology has been reflected in the most
recent EORTC clinical guidelines, which recommend bio-
similar filgrastim as well as originator filgrastim to prevent
chemotherapy-induced neutropenia, with choice of formulation
considered as a matter of individual clinical judgement [6].
The development of biosimilars offers many potential ben-
efits to patients, physicians and healthcare providers, includ-
ing enhanced affordability and increased access to expensive
biological treatments. However, the arrival of biosimilars in
the clinic has not been without debate, and several questions
have been raised over their use [7–11]. These concerns have
focused on issues related to consistent product quality and
efficacy, immunogenicity, safety, labelling, traceability, auto-
matic substitution, and extrapolation to other indications. As it
has been over 5 years since the first biosimilar was approved
in Europe, it now seems an appropriate time to review the
evidence relating to these topics. Here, we perform this task
and report a pooled analysis of post-approval studies of
Zarzio® used for the prevention of neutropenia in patients
with cancer undergoing cytotoxic chemotherapy.
Biosimilar quality and efficacy
Extensive physicochemical and biological characterisation
using an array of standard and advanced analytical tests is a
key aspect of the approval process for biosimilars. As a result
of this stringent approach, the quality of biosimilars has
generally been shown to compare favourably with originator
biopharmaceutical products. For instance, analyses have in-
dicated that biosimilar G-CSF may contain fewer impurities
and less modified products than the originator [12]. For
Zarzio®, protein structure, mass, size, charge and hydropho-
bicity were shown to be identical to Neupogen® using an
array of analytical tests [13]. Bioactivity was also shown to
be similar to the originator, with comparable binding to the
G-CSF receptor in a surface plasmon resonance-based re-
ceptor affinity test and comparable biological activity in an
in vitro cell proliferation assay. Similar protein characterisa-
tion results have been reported for Nivestim® [14] and
confirm the physicochemical and biological comparability
of biosimilar G-CSF with the originator.
In terms of efficacy, the EMA guidelines on biosimilar G-
CSF state that pharmacodynamic (PD) studies may be suffi-
cient to demonstrate comparability [1]. Therefore, clinical de-
velopment of Zarzio® focused on PD responses in healthy
subjects rather than comparative phase III clinical data. Studies
in healthy volunteers may be especially useful to evaluate the
haematopoietic effect of filgrastim since their bone marrow is
more responsive to G-CSF than that of patients with cancer
undergoing chemotherapy. The bioequivalence of Zarzio® and
Neupogen® was shown in four comparative phase I studies
involving a total of 146 healthy adult volunteers [15], in which
both products had comparable effects on absolute neutrophil
count (ANC) and CD34+ cell count, which were used as
surrogate markers of efficacy. Pharmacokinetic (PK) parame-
ters also showed bioequivalence of Zarzio® and Neupogen®.
Data in patients with cancer were provided by a phase III
study designed primarily to assess safety. The study was
conducted in 170 patients with stage II–IV breast cancer re-
ceiving cytotoxic chemotherapy with doxorubicin (60 mg/m2)
and docetaxel (75 mg/m2). Zarzio® was shown to be effective
in these patients, with the duration of severe grade 4 neutrope-
nia and incidence of febrile neutropenia comparable with
published results for the originator product [16, 17].
Similarly, clinical comparability with the originator has been
shown for the other two biosimilar G-CSF products. Although
there were differences between the clinical development
programmes for the three biosimilars, with differing degrees of
emphasis on PK/PD characterisation and thus the need for
subsequent clinical trial data, all have been approved as being
similar to the originator product based on a combination of
protein characterisation, PK and PD in healthy volunteers and
efficacy and safety in patients. For Tevagrastim®/Ratiograstim®,
development included two PK/PD studies [18, 19] and three
phase III studies (in breast cancer, lung cancer and non-
Hodgkin's lymphoma) [20–22], while development of
Nivestim® involved two PK/PD studies [23, 24] and a single
phase III study in patients with breast cancer [25].
Despite the robustness of the non-clinical and clinical eval-
uations that are necessary for approval of a biosimilar, concerns
have been raised over whether biosimilars are effective in the
real-world clinical practice setting. To investigate this, we
conducted an analysis of pooled data from five post-approval
studies in which Zarzio® was used for the prophylaxis of
chemotherapy-induced neutropenia in patients with cancer.
Pooled analysis of post-approval studies of Zarzio®
for prevention of chemotherapy-induced neutropenia
Data were pooled from five studies investigating the real-life
clinical usage of Zarzio® for the primary or secondary prophy-
laxis of chemotherapy-induced neutropenia in patients with can-
cer (Table 1) [26–30]. These studies were conducted across 12
European countries and consisted of two ongoing multicentre
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observational studies (interim data) plus three single-centre ob-
servational studies. Patients were included in the analysis if they
were aged ≥18 years, had a confirmed diagnosis of cancer and
received at least one cycle of chemotherapy with Zarzio®. Since
all studies were non-interventional, patients were treated with
Zarzio® on the basis of the individual physicians' clinical judge-
ment and according to standard local practice. Patients receiving
Zarzio® for the treatment of neutropenia (rather than prophylax-
is) were excluded from the analysis.
Data from 1,302 patients were included in the analyses. The
most frequent cancer types were breast cancer (n=541; 42 %),
lung cancer (n=212; 16 %) and lymphoma/leukaemia (n=201;
15 %) (Fig. 1). Based on chemotherapy regimen, 36 % of
patients were estimated to have had a febrile neutropenia risk
of >20 %, while 40 % had a risk of 10–20 %. A further 12 % of
patients received Zarzio® despite a febrile neutropenia risk of
<10 % (12 % unknown) (Fig. 2). Twice as many patients
received biosimilar G-CSF as primary prophylaxis (57 %) com-
pared with secondary prophylaxis (27 %) (16 % unknown)
(Fig. 3).
Overall, only 2.2 % (n=29) of patients experienced an epi-
sode of febrile neutropenia (2.0% of patients with breast cancer),
and 8.5 % (n=104) of patients had severe (grade 4) neutropenia
(ANC <500/μL) (9.4 % in patients with breast cancer). Both
febrile neutropenia and severe neutropenia were approximately
twice as likely to occur in patients receiving Zarzio® as second-
ary rather than primary prophylaxis (3.1 versus 1.6 % and 7.4
versus 13.1 % of patients, respectively). Disturbances to chemo-
therapy regimens (dose reduction or discontinuation) were re-
ported in two studies, occurring in 8/77 patients (10 %) in one
study [28] and 27/307 patients (7 %) in the other [27].
The occurrence of severe or febrile neutropenia observed
in the pooled analysis was within the range of that observed
in previous studies of G-CSF [31, 32]. Overall, this new
pooled analysis demonstrates that Zarzio® appears to be
effective for the prevention of chemotherapy-induced neu-
tropenia in clinical practice across a variety of cancers.
Safety
The EMA sets strict guidelines for a market authorisation holder
in terms of both product-specific risk management plans and
overarching guidance for pharmacovigilance. Since the launch of
Zarzio® in 2009, the estimated exposure to this biosimilar is
approximately 4.5 million patient days (as of June 2013 Sandoz
data on file). To date, clinical experience has revealed no striking
or new safety signals for Zarzio®. In the phase III study, Zarzio®
Table 1 Studies included in
pooled analysis of post-approval
studies of Zarzio® in patients
with cancer undergoing cytotox-
ic chemotherapy
EOC endometrial/ovarian can-
cer, PP primary prophylaxis,MC
multicentre, SC single centre, SP
secondary prophylaxis
Study Patients (n) Cancer types Type of prophylaxis
MONITOR G-CSF (MC) 741 Breast, n=236 PP, n=409
Gascon et al. 2011 [26] Lung, n=160 SP, n=129






HexaFil (MC) 394 Breast, n=258 PP, n=219




Hamburg, Germany (SC) 77 Breast, n=22 PP, n=32
Verpoort et al. 2011 [28] Lymphoma/leukaemia, n=17 SP, n=40
Colorectal, n=10 Unknown, n=5
Other, n=28
Gaeta, Italy (SC) 48 Lung, n=17 PP, n=37




Rosati et al. 2011 [30] 42 Breast, n=15 PP, n=42
Other solid, n=27
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was generally well tolerated [15], a finding supported by the
pooled analysis in which the safety profile of Zarzio® was
consistent with that reported for originator G-CSF and the known
G-CSF adverse event profile. Of particular note, occurrence of
bone pain was 8 % (reported in [27]), consistent with that
observed in the phase III study and in line with reported inci-
dence with the originator [16, 17]. The relatively low incidence
compared with that observed in clinical studies of originator G-
CSF (24 % across all phase II/III studies) may be because bone
pain is a recognised common side effect of G-CSF treatment and
so may be less likely to be reported in everyday practice than
other less expected side effects.
One particular concern with biosimilars has been the
potential for an immunological response that may differ from
that seen with the originator. EMA states that an appropriate
strategy for assessment of unwanted immunogenicity of
biological products is essential and should include validated
state-of-the-art assays able to detect neutralising and non-
neutralising antibodies. For Zarzio®, no neutralising anti-
bodies were detected in any of the clinical studies in healthy
volunteers or cancer patients (n=316). In addition, no reports
of neutralising antibodies have occurred during the ongoing
pharmacovigilance of Zarzio® in clinical use. Pharmacovigilance
is necessary to detect rare adverse events that can only be
detected in a larger patient population during long-term use and
is required for all biologicals, including original products. The
lack of reports of antibody development to Zarzio® is unsurpris-
ing given that filgrastim is an unglycosylated protein mostly
administered to immunocompromised patients and the absence
of immunogenicity seen with the originator product.
Traceability and automatic substitution
Traceability refers to the need to be able to identify individual
medical products and is essential for accurate pharmacovigilance.
Biosimilars generally have the same international non-proprie-
tary name (INN) as the originator product. In the case of
biosimilar G-CSFs, their common INN is filgrastim. Several
health regulatory agencies have highlighted the need for clini-
cians to identify specific products by brand name, as did the
recent update to EORTC guidelines on the use of G-CSF to













600Fig. 1 Pooled analysis of post-
approval studies of Zarzio® in
patients with cancer undergoing
cytotoxic chemotherapy: most
frequent solid tumours and
haematological malignancies
(n=1,302)
Fig. 2 Pooled analysis of post-approval studies of Zarzio® in patients
with cancer undergoing cytotoxic chemotherapy: febrile neutropenia






Fig. 3 Pooled analysis of post-approval studies of Zarzio® in patients
with cancer undergoing cytotoxic chemotherapy: type of prophylaxis
(n=1,302). PP primary prophylaxis, SP secondary prophylaxis
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In accordancewith such guidance, biosimilarmanufacturers have
marketed products under clearly branded names and packaging.
Another related concern is that of drug substitution, whereby
a prescribed product is replaced by another with the same INN
by the pharmacist. Generally, the decision to treat a patient with
an originator or biosimilar product should be taken by a qual-
ified healthcare professional. EORTC G-CSF clinical guide-
lines state that no changes in product should be made without
informing both physician and patient [6]. The EU allows
member countries to set their own policy regarding substitution
and many have taken specific measures at a regulatory/legal
level to prevent automatic substitution of biologicals, although
not all countries have a clear position to date.
Extrapolation to other indications
Another question raised regarding biosimilars relates to the
extrapolation of clinical data, a process that may allow the
approval of a product for use in indications in which it has
not been evaluated in clinical trials. The validity of data
extrapolation is dependent on the biosimilar having the same
mechanism of action as the originator, and the mechanism of
action being the same in different indications. As such, data
extrapolation is generally considered rational and appropriate by
the EMAwhen comparability between a biosimilar and origina-
tor in one indication can be reasonably assumed to be extended
to other indications for which the originator is approved.
In the case of biosimilar G-CSF, approval has been pri-
marily on the basis of studies in healthy volunteers and for
the prevention of chemotherapy-induced neutropenia. How-
ever, since approval is given for the same indications as the
originator, biosimilar G-CSF can also be used for peripheral
blood stem cell (PBSC) mobilisation, including neutrophil
recovery after stem cell transplantation. Extrapolation to all
indications of the reference product was considered accept-
able on the basis of phase I data especially since comparable
receptor site kinetics of the two products indicate that the
mode of action is the same for both, i.e. direct stimulation of
bone marrow cells through the G-CSF surface receptor.
In support of this, phase I studies showed PD and PK
comparability between Zarzio® and Neupogen® at doses
typically used for stem cell mobilisation (10 μg/kg) [15].
Subsequently, several studies have indicated that use of
biosimilar G-CSF in the haematopoietic stem cell transplant
(HSCT) setting is well tolerated and effective, with comparable
results to those observed with originator G-CSF. In one study,
40 patients with haematological malignancy who were sched-
uled to receive Zarzio® following first-cycle chemotherapy for
autologous PBSC mobilisation were compared with a matched
historical control group (n=41) who had been treated with
Neupogen® at the same centre [33]. No significant differences
between groups were observed in the median number of CD34+
cells collected in the first leukapheresis or in the number of
leukaphereses necessary to obtain the minimum CD34+ cell
count. Similar results were observed in a study of 38 patients
with lymphoma or myeloma who received Zarzio® and who
were compared with a historical cohort of such patients treated
with Neupogen® (n=50) [34]. No significant differences in
PBSC stimulation or biological parameters of bone marrow
recovery were observed between the two cohorts. Several other
studies have also reported comparability of biosimilar G-CSF
and the originator when used for stem cell transplantation
[35–38].
Relative to the experience gathered in autologous HSCT, use
of biosimilar G-CSFs in allogeneic HSCT has been more limit-
ed. Accordingly, some concerns have been raised over the use of
G-CSFs in healthy donors, especially with regard to long-term
safety outcomes. For instance, the World Marrow Donor Asso-
ciation has recommended that biosimilar G-CSF should not be
used for mobilisation in healthy donors, unless participating in a
clinical study (Shaw et al. 2011) [39]. However, initial data
suggest that there are at least no short-term safety concerns. In
one small study of 21 donors, Azar et al. reported that Zarzio®
was effective and well tolerated [40]. Another biosimilar G-CSF,
Ratiograstim®, has been reported to possess similar efficacy to
originator G-CSF when given to 22 healthy donors during
allogeneic HSCT [41]. A long-term safety study of Zarzio® in
200 healthy stem cell donors is ongoing, with an interim data
analysis having reported no unexpected results that would ques-
tion the safety of Zarzio® for healthy donor stem cell
mobilisation (Becker et al. 2012) [42] .
Pharmacoeconomic considerations
Global healthcare costs have increased dramatically in recent
years, forcing healthcare authorities to consider various
means to help contain expenditure [43]. Biosimilars may
offer one route to reduced healthcare costs and improved
patient access to treatments [44]. However, since biosimilar
development and manufacturing involves considerable in-
vestment of time and expertise, there were concerns that the
cost savings generated may not be as great as was originally
predicted. However, these concerns appear to have been
largely unfounded, with significant cost savings being re-
ported through the adoption of biosimilars.
Experience from health authority regions that have
switched from originator G-CSF to Zarzio® suggests that
significant cost savings can be achieved. For instance, across
the London region, switching from originator G-CSF to
Zarzio® was associated with an estimated annual cost-
saving of £1 million, with G-CSF purchasing costs being
reduced from £3.3 million in 2010 to £2.3 million in 2011.
This saving was predicted to increase to £2 million in 2012 as
the switch to biosimilar G-CSF usage continues (personal
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communication, Antony Grosso, London Procurement Pro-
gramme, September 2012). Similarly, in the Southern Health
Care region in Sweden (population 1.7 million), the shift from
originator to biosimilar G-CSF has led to a fivefold increase in
daily G-CSF usage (based on data provided by IMSHealth [45],
the SwedishDental and Pharmaceutical Benefits Agency (www.
tlv.se) and Skåne University Hospital). Importantly, this region
previously had restrictions on G-CSF usage to prevent febrile
neutropenia that have been relaxed with the switch to biosimilar.
The introduction of biosimilar G-CSF in this region was associ-
atedwith net savings of €2million - this represents a saving of 4–
5 % of the total drug budget. Moreover, data from IMS suggest
that annual savings in 2011 resulting from the use of biosimilar
(Zarzio®) rather than originator G-CSF amounted to €85million
across 17 EU countries (estimate based on originator G-CSF
prices and sales volume obtained from IMS Health [45]
biosimilar G-CSF sales including estimated level of discount
based on Sandoz data on file).
As shown by the Swedish example, the increased affordability
of biosimilar G-CSF may improve patient access to G-CSF and
encourage physicians to more closely adhere to clinical guideline
recommendations. Evidence to support this is also provided from
the UK, where the availability of biosimilar G-CSF (September
2008) resulted in a 13 % increase in overall G-CSF use from
2008 to 2009 and a further 17 % increase from 2009 to 2010.
This increase in use is illustrated by the experience of the
Haematology Department, Rotherham Hospital, Rotherham,
UK, where the decision to switch from originator G-CSF to
Zarzio® by the purchasing consortium was a factor contributing
to a shift in treatment practice from secondary prophylaxis to
increased primary prophylaxis, especially in patients receiving
chemotherapy with a febrile neutropenia risk of 10–20 %. Re-
cently published experience from a single centre in Hamburg,
Germany, also reports that switching from originator to
biosimilar G-CSF was accompanied by a trend towards an
increased use of G-CSF as primary prophylaxis (52 % versus
36 % of patients), which may have reflected increased willing-
ness to use G-CSF earlier, given its lower cost [28].
In addition to increased access to G-CSF, cost savings
achieved through biosimilar use can be redistributed to offset
budgetary constraints elsewhere, in particular, to improve
access to new cancer treatments and/or reduce workforce
cost-saving pressures.
Conclusions
Biosimilar products have been available in Europe and else-
where for several years. These products are manufactured with
state-of-the-art technology and have passed the regulatory re-
quirements for approval. A recent review authored by members
and experts of the Working Party on Similar Biological Medic-
inal Products of the EMA concluded that principles guiding
biosimilar development are scientifically sound and that ap-
proved biosimilars can be considered as therapeutic alternatives
to the reference product [46]. Initial concerns about efficacy and
safety appear to be unfounded as, for example, an increasing
body of clinical evidence suggests that biosimilar G-CSFs
compare favourably with the originator product. Recent
EORTC guidelines for the prevention of chemotherapy-
induced neutropenia now recognise biosimilar G-CSF as an
alternative to the originator [6]. However, it should be noted
that implementation of EORTC guidelines is varied with many
scenarios where physicians chose to ‘wait and see’, often
waiting for neutrophils to decrease or neutropenic symptoms
to occur before intervening. There aremany reasons for this, but
cost containment is very likely to be one of them. One benefit of
biosimilars is that their greater affordability may encourage
earlier use of G-CSF and improve congruence with guidelines.
Strict pharmacovigilance and data monitoring should continue
to examine the long-term efficacy and safety of biosimilars, and
this information must be clearly disseminated to patients, clini-
cians and other stakeholders. Nevertheless, in the current cli-
mate of growing financial constraints on healthcare cost sys-
tems, biosimilars offer an affordable, high-quality and clinically
effective alternative. Thus, increasing adoption of biosimilars
should help reduce healthcare budgets and improve access to
expensive biological treatments for patients.
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